0JDM.L - IQVIA Holdings Inc.
| Previous close | 195.53 |
| Open | 197.95 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 197.46 - 198.82 |
| 52-week range | 166.56 - 247.57 |
| Volume | |
| Avg. volume | 2,863 |
| Market cap | 395.723M |
| Beta (5Y monthly) | 1.39 |
| PE ratio (TTM) | 0.36 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
IQVIA & (RED) Announce Groundbreaking Partnership to Support Laboratory System Strengthening
RESEARCH TRIANGLE PARK, N.C., May 25, 2023--IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life science industry, announced a groundbreaking partnership today with (RED), the organization co-founded by Bono and Bobby Shriver to fight AIDS and the injustices that enable pandemics to thrive, to support laboratory system strengthening and save lives.
- Business Wire
Global Oncology R&D Activity Remains High and More Patients Have Been Treated for Cancer, says IQVIA Institute for Human Data Science
RESEARCH TRIANGLE PARK, N.C., May 24, 2023--Global research and development activity in oncology remained at historically high levels in 2022, up 22% from 2018, and the global number of patients treated with approved medicines increased at an average of 5% annually over the same period, according to a new report from the IQVIA Institute for Human Data Science on Global Oncology Trends 2023. Over the last five years, a total of 115 novel active substances in oncology have launched globally; simul
- Business Wire
IQVIA Announces Pricing of Upsized Offering of Senior Secured Notes and Senior Notes
INNOVATION PARK, N.C., May 18, 2023--IQVIA Holdings Inc. (NYSE:IQV) today announced that its wholly-owned subsidiary, IQVIA Inc. (the "Issuer"), priced an offering of $1,250,000,000 in aggregate principal amount of senior notes, which was upsized due to strong demand, consisting of $750,000,000 in aggregate principal amount of senior secured notes due 2028 (the "Senior Secured Notes") and $500,000,000 in aggregate principal amount of senior notes due 2030 (the "Senior Notes" and, together with t
- Business Wire
IQVIA Announces Offering of Senior Secured Notes and Senior Notes
INNOVATION PARK, N.C., May 18, 2023--IQVIA Holdings Inc. (NYSE:IQV) today announced that its wholly-owned subsidiary, IQVIA Inc. (the "Issuer"), intends to raise $1,000,000,000 through an offering of senior secured notes due 2028 and senior notes due 2030 (collectively, the "Notes").
- Business Wire
IQVIA Celebrates Sheetal Telang, Winner of Healthcare Businesswoman's Association Rising Star Award
RESEARCH TRIANGLE PARK, N.C., May 11, 2023--IQVIA (NYSE:IQV) today announced that Sheetal Telang, vice president of Therapeutic Strategy, has been honored with the 2023 Rising Star award by the Healthcare Businesswoman's Association (HBA).
- Business Wire
Use of Medicines in the U.S. Continued to Grow in 2022 while Patient Out-of-Pocket Costs Remain Low, Says IQVIA Institute
RESEARCH TRIANGLE PARK, N.C., May 02, 2023--The U.S. market for medicines grew by 5% in 2022, reaching a total value of $429Bn on a net price basis. This was driven by a range of factors, including an increase in health services utilization, which is now back to pre-pandemic levels, and the entry of new medicines into the market. Balancing these drivers of growth, was a lack of net price increases for branded drugs and patient out-of-pocket costs per retail prescription remaining under $10. This
- Business Wire
IQVIA Reports First-Quarter 2023 Results; Reaffirms Full-Year 2023 Guidance
RESEARCH TRIANGLE PARK, N.C., April 27, 2023--IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today reported financial results for the quarter ended March 31, 2023.
- Business Wire
IQVIA Named a Leader in Everest Group Life Sciences Customer Experience Platforms PEAK Matrix® Assessment 2023
RESEARCH TRIANGLE PARK, N.C., April 20, 2023--IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the pharmaceutical and broader life sciences industry, today announces the company has been recognized as a Leader in Customer Experience Platforms (CXP) by Everest Group for its Orchestrated Customer Engagement (OCE) platform.
- Business Wire
IQVIA to Announce First-Quarter 2023 Results on April 27, 2023
RESEARCH TRIANGLE PARK, N.C., April 06, 2023--IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) will announce its first-quarter 2023 financial results before the market opens on Thursday, April 27, 2023. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com.
- Business Wire
Global Clinical Trial Activity Remained Resilient in 2022 Despite The Continued Pandemic, Says IQVIA Institute
RESEARCH TRIANGLE PARK, N.C., March 14, 2023--In 2022, global clinical trial activity remained resilient even as the COVID-19 pandemic stretched through the year, with a 1% decline in non-COVID trial activity compared to 2021. COVID-19 trials as a percentage of total trial activity dropped from 10% to 6% of the 5,756 total trials run in 2022. Non-COVID trial activity increased by 8% between 2019 and 2022, suggesting a restoration to pre-pandemic growth rates, according to a new report, Global Tr
- Business Wire
IQVIA CFO Ron Bruehlman to Speak at Barclays Global Healthcare Conference on March 15, 2023
RESEARCH TRIANGLE PARK, N.C., March 01, 2023--IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Barclays Global Healthcare Conference in Miami, FL on Wednesday, March 15, 2023 at 9:30 a.m. ET.
- Business Wire
IQVIA Publishes its 2022 Environmental, Social and Governance Report
RESEARCH TRIANGLE PARK, N.C., February 23, 2023--IQVIA (NYSE:IQV) has published its 2022 Environmental, Social and Governance (ESG) Report. The annual report provides a detailed account of the organization’s focus on reducing its environmental impact and commitment to accelerating positive outcomes for public health and patients.
- Business Wire
IQVIA Reports Fourth-Quarter and Full-Year 2022 Results; Issues Full-Year 2023 Guidance
RESEARCH TRIANGLE PARK, N.C., February 10, 2023--IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today reported financial results for the quarter ended December 31, 2022.
- Business Wire
IQVIA Named to FORTUNE’s 2023 List of "World’s Most Admired Companies," Ranked #1 in Its Category for the Second Consecutive Year
RESEARCH TRIANGLE PARK, N.C., February 09, 2023--IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, has been named to FORTUNE magazine’s "World’s Most Admired Companies" list for the sixth consecutive year.
- Business Wire
IQVIA in Collaboration with Alibaba Cloud to Deliver Commercial & Clinical Solutions in China
RESEARCH TRIANGLE PARK, N.C., January 31, 2023--IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the pharmaceutical and broader life sciences industry, today announces the first life sciences industry collaboration with Alibaba Cloud in China. IQVIA and Alibaba Cloud, the digital technology and intelligence backbone of Alibaba Group, will be providing solutions hosted in Mainland China leveraging Salesforce on Alibaba Clou
- Business Wire
IQVIA to Announce Fourth-Quarter and Full-Year 2022 Results on February 10, 2023
RESEARCH TRIANGLE PARK, N.C., January 25, 2023--IQVIA Holdings Inc. ("IQVIA") (NYSE: IQV) will announce its fourth-quarter and full-year 2022 financial results before the market opens on Friday, February 10, 2023. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com.
- Business Wire
Global Market for Medicines to Rise to $1.9 Trillion by 2027, says Report from IQVIA Institute
RESEARCH TRIANGLE PARK, N.C., January 18, 2023--The total spending and global demand for medicines will increase over the next five years to approximately $1.9 trillion by 2027, according to a new report titled Global Use of Medicines 2023 – Outlook through 2027 from the IQVIA Institute for Human Data Science.
- PR Newswire
Lasso announces a significant step forward in healthcare marketing measurement
Lasso, an IQVIA (IQV) business and provider of a leading healthcare marketing and analytics operating system, announced the integration of IQVIA's AIM XR (Audience Identity Manager® XR) into their operating system, giving over 4,000 medical publishers access to timely insights on campaign reach and effectiveness. Lasso's Measurement Suite is immediately available to all AIM XR partners.
- PR Newswire
Biostage Selects IQVIA to Manage its FDA-Approved Clinical Trial in Severe Esophageal Disease, including Cancer
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a clinical-stage biotechnology company developing regenerative-medicine treatments for disorders of the gastro-intestinal system and the airway resulting from cancer, trauma or birth defects, today announced that it had selected IQVIA, a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, as the contract research organization (CRO) to manage its first clinical
- Business Wire
IQVIA and Clalit Health Services partner to advance research by launching the first Prime Site in Israel
RESEARCH TRIANGLE PARK, N.C., November 10, 2022--IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced a long-term collaboration with Clalit, the largest health services organization in Israel, to launch the first Prime Site in the country.
- Business Wire
IQVIA Reports Third-Quarter 2022 Results
RESEARCH TRIANGLE PARK, N.C., October 26, 2022--IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today reported financial results for the quarter ended September 30, 2022.
- Business Wire
IQVIA CFO Ron Bruehlman to Speak at Credit Suisse Annual Healthcare Conference on November 8, 2022
RESEARCH TRIANGLE PARK, N.C., October 24, 2022--IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Credit Suisse Annual Healthcare Conference in Rancho Palos Verdes on Tuesday, November 8, 2022 at 12:10 p.m. ET (9:10 a.m. PT).
- Business Wire
Q² Solutions Launches Innovative Self-Collection Safety Lab Panel in Collaboration With Tasso
RESEARCH TRIANGLE PARK, N.C., October 06, 2022--Q² Solutions, a wholly owned subsidiary of IQVIA and a leading global clinical trial laboratory services organization, today announced the launch of the first self-collection safety lab panel for U.S. clinical trial participants by a leading global clinical trial laboratory.
- Business Wire
IQVIA to Announce Third-Quarter 2022 Results on October 26, 2022
RESEARCH TRIANGLE PARK, N.C., October 03, 2022--IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) will announce its third-quarter 2022 financial results before the market opens on Wednesday, October 26, 2022. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com.
- Business Wire
IQVIA Decentralized Clinical Trial Program Achieves Independent GDPR Validation
RESEARCH TRIANGLE PARK, N.C., September 28, 2022--IQVIA (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and contract services to the life sciences industry, today announced its Decentralized Clinical Trial (DCT) program has received GDPR compliance validation from TRUSTArc. This marks the first instance of a DCT service receiving this European data privacy validation.
